Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
NCT ID: NCT02614183
Last Updated: 2020-06-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
862 participants
INTERVENTIONAL
2015-11-30
2018-08-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
NCT02614196
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache
NCT02163993
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
NCT05127486
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
NCT02614261
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
NCT02614287
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Galcanezumab 120mg
Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.
Galcanezumab
Administered SC
Galcanezumab 240mg
Galcanezumab 240mg given by SC injection once a month for 6 months.
Galcanezumab
Administered SC
Placebo
Placebo given by SC injection once a month for 6 months.
Placebo
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Galcanezumab
Administered SC
Placebo
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Current use or prior exposure to Galcanezumab or another CGRP antibody.
* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to Galcanezumab.
* History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Territory Neurology & Research Institute
Tucson, Arizona, United States
Orange Grove Family Practice
Tucson, Arizona, United States
Arkansas Clinical Research
Little Rock, Arkansas, United States
Advanced Clinical Research
Carmichael, California, United States
Pharmacology Research Institute, Newport Beach
Encino, California, United States
Tooraj Joseph Raoof M.D., Inc.
Encino, California, United States
Fullerton Neurology and Headache Center
Fullerton, California, United States
Sun Valley Research Center
Imperial, California, United States
Irvine Clinical Research Center
Irvine, California, United States
Pharmacology Research Institute, Newport Beach
Los Alamitos, California, United States
Pharmacology Research Institute, Newport Beach
Newport Beach, California, United States
Desert Valley Research
Rancho Mirage, California, United States
Anderson Clinical Research
Redlands, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
Medical Center for Clinical Research
San Diego, California, United States
Alpine Clinical Research Center
Boulder, Colorado, United States
MCB Clinical Research Centers
Colorado Springs, Colorado, United States
Mile High Research Center
Denver, Colorado, United States
Colorado Neurological Institute
Englewood, Colorado, United States
Advanced Neurosciences Research, LLC
Fort Collins, Colorado, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Meridien Research
Bradenton, Florida, United States
Sarkis Clinical Trials
Gainesville, Florida, United States
Suncoast Clinical Research
New Port Richey, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Sensible Healthcare
Ocoee, Florida, United States
Psychiatric Inst of Florida-Clinical Neuroscience Solutions
Orlando, Florida, United States
Compass Research
Oviedo, Florida, United States
Accord Clinical Research, LLC
Port Orange, Florida, United States
Roskamp Institute
Sarasota, Florida, United States
Infinity Clinical Reserach . LLC
Sunrise, Florida, United States
Premiere Research Institute at Palm Beach Neurology
West Palm Beach, Florida, United States
Advanced Clinical Research LLC
Meridian, Idaho, United States
Healthcare Research Network - Blue Island
Blue Island, Illinois, United States
Community Clinical Research Center
Anderson, Indiana, United States
Investigative Clinical Research of Indiana, LLC
Elwood, Indiana, United States
Midwest Institute for Clinical Research
Indianapolis, Indiana, United States
Deaconess Clinic Inc
Newburgh, Indiana, United States
Integrated Clinical Trial Services, Inc.
West Des Moines, Iowa, United States
Phoenix Medical Research, Inc
Prairie Village, Kansas, United States
Otri-Med Corporation
Edgewood, Kentucky, United States
L-Marc Research Center
Louisville, Kentucky, United States
PharmaSite Research Inc
Baltimore, Maryland, United States
Boston Clinical Trials Inc
Boston, Massachusetts, United States
Michigan Head, Pain and Neurological Institute
Ann Arbor, Michigan, United States
Clinical Research Institute
Minneapolis, Minnesota, United States
ClinVest
Springfield, Missouri, United States
Healthy Perspectives Innovative Mental Health Services, PL
Nashua, New Hampshire, United States
Albuquerque Clinical Trials
Albuquerque, New Mexico, United States
Dent Neurological Institute
Amherst, New York, United States
Central New York Clinical Research
Manlius, New York, United States
NYU Langone
New York, New York, United States
Fieve Clincial Services
New York, New York, United States
Rochester Clinical Research, Inc.
Rochester, New York, United States
Metrolina Neurological Associates, PA
Charlotte, North Carolina, United States
Headache Wellness Center
Greensboro, North Carolina, United States
Rapid Medical Research Inc
Cleveland, Ohio, United States
Medical College of Ohio at Toledo
Toledo, Ohio, United States
Healthcare Research Consultant
Tulsa, Oklahoma, United States
Summit Research Network Inc
Portland, Oregon, United States
Lehigh Center for Clinical Research
Allentown, Pennsylvania, United States
Preferred Primary Care Physicians
Pittsburgh, Pennsylvania, United States
Abington Neurological Associates
Willow Grove, Pennsylvania, United States
Omega Medical Research
Warwick, Rhode Island, United States
Clinical Trials of South Carolina
Charleston, South Carolina, United States
8 Medical Park
Columbia, South Carolina, United States
ClinSearch
Chattanooga, Tennessee, United States
University of Tennessee Medical Center
Knoxville, Tennessee, United States
Clinical Research Associates
Nashville, Tennessee, United States
FutureSearch Trials
Austin, Texas, United States
Protenium Clinical Research
Hurst, Texas, United States
Clinical Trials of Texas, Inc.
San Antonio, Texas, United States
Radiant Research - San Antonio
San Antonio, Texas, United States
Advanced Clinical Research
West Jordan, Utah, United States
Charlottesville Medical Research
Charlottesville, Virginia, United States
Clinical Research Associates of Tidewater
Norfolk, Virginia, United States
National Clinical Research - Richmond
Richmond, Virginia, United States
Premier Clinical Research
Spokane, Washington, United States
Vancouver Clinic
Vancouver, Washington, United States
Clinical Investigation Specialists Inc
Kenosha, Wisconsin, United States
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
Brampton, , Canada
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
Kelowna, , Canada
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
Mississauga, , Canada
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
Montreal, , Canada
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
Ottawa, , Canada
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
Sherbrooke, , Canada
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
Toronto, , Canada
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
Vancouver, , Canada
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
Waterloo, , Canada
Office of Dr. Ruddy Guerra
ManatÃ, , Puerto Rico
NuFrontiers Clinical Research LLC
Rio Piedras, , Puerto Rico
Clinical Research Puerto Rico, Inc.
San Juan, , Puerto Rico
GCM Medical Group PSC
San Juan, , Puerto Rico
Instituto de Neurologia Dra. Ivonne Fraga
San Juan, , Puerto Rico
Neuro GI Wellness Center
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ailani J, Kuruppu DK, Rettiganti M, Oakes T, Schroeder K, Wietecha L, Port M, Blumenfeld AM. Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials. Headache. 2022 Feb;62(2):198-207. doi: 10.1111/head.14257. Epub 2022 Jan 25.
Citrome L, Sanchez Del Rio M, Dong Y, Nichols RM, Tockhorn-Heidenreich A, Foster SA, Stauffer VL. Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm. Adv Ther. 2021 Aug;38(8):4442-4460. doi: 10.1007/s12325-021-01848-x. Epub 2021 Jul 15.
Jedynak J, Eross E, Gendolla A, Rettiganti M, Stauffer VL. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials. J Headache Pain. 2021 May 28;22(1):48. doi: 10.1186/s10194-021-01222-w.
Pozo-Rosich P, Samaan KH, Schwedt TJ, Nicholson RA, Rettiganti M, Pearlman EM. Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis. Adv Ther. 2021 Jun;38(6):3154-3165. doi: 10.1007/s12325-021-01708-8. Epub 2021 May 5.
Ament M, Day K, Stauffer VL, Skljarevski V, Rettiganti M, Pearlman E, Aurora SK. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. J Headache Pain. 2021 Feb 6;22(1):6. doi: 10.1186/s10194-021-01215-9.
Kuruppu DK, North JM, Kovacik AJ, Dong Y, Pearlman EM, Hutchinson SL. Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials. Adv Ther. 2021 Mar;38(3):1614-1626. doi: 10.1007/s12325-021-01632-x. Epub 2021 Feb 5.
Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia. 2021 Mar;41(3):340-352. doi: 10.1177/0333102420966658. Epub 2020 Nov 3.
Ailani J, Andrews JS, Rettiganti M, Nicholson RA. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials). J Headache Pain. 2020 Oct 17;21(1):123. doi: 10.1186/s10194-020-01190-7.
Stauffer VL, Turner I, Kemmer P, Kielbasa W, Day K, Port M, Quinlan T, Camporeale A. Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials. J Headache Pain. 2020 Jun 23;21(1):79. doi: 10.1186/s10194-020-01148-9.
Bangs ME, Kudrow D, Wang S, Oakes TM, Terwindt GM, Magis D, Yunes-Medina L, Stauffer VL. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020 Jan 17;20(1):25. doi: 10.1186/s12883-020-1609-7.
Kielbasa W, Quinlan T. Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine. J Clin Pharmacol. 2020 Feb;60(2):229-239. doi: 10.1002/jcph.1511. Epub 2019 Sep 4.
Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain. 2019 Jun 28;20(1):75. doi: 10.1186/s10194-019-1024-x.
Stauffer VL, Wang S, Voulgaropoulos M, Skljarevski V, Kovacik A, Aurora SK. Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials. Headache. 2019 Jun;59(6):834-847. doi: 10.1111/head.13508. Epub 2019 Apr 3.
Forderreuther S, Zhang Q, Stauffer VL, Aurora SK, Lainez MJA. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain. 2018 Dec 29;19(1):121. doi: 10.1186/s10194-018-0951-2.
Nichols R, Doty E, Sacco S, Ruff D, Pearlman E, Aurora SK. Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies. Headache. 2019 Feb;59(2):192-204. doi: 10.1111/head.13443. Epub 2018 Nov 21.
Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018 Sep 1;75(9):1080-1088. doi: 10.1001/jamaneurol.2018.1212.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information about this study: Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I5Q-MC-CGAG
Identifier Type: OTHER
Identifier Source: secondary_id
15767
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.